Clinical Trials Logo

Adenoid Cystic Carcinoma clinical trials

View clinical trials related to Adenoid Cystic Carcinoma.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06462183 Not yet recruiting - Colorectal Cancer Clinical Trials

Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)

Start date: June 2024
Phase: Phase 1
Study type: Interventional

Phase 1 study to evaluate safety, tolerability and anti-tumor activity of RGT-61159 in patients with ACC or CRCT

NCT ID: NCT06322576 Not yet recruiting - Clinical trials for Adenoid Cystic Carcinoma

177Lu-PSMA (177Lu-PNT2002) in PSMA-Positive Adenoid Cystic Carcinoma

Start date: July 2024
Phase: Phase 2
Study type: Interventional

This is a single arm trial with one Cohort for people with recurrent or metastatic adenoid cystic carcinoma that cannot be treated with surgery. 10 participants will be enrolled in Cohort 1 at Johns Hopkins and will undergo DCFPyL PET/CT and 177Lu-PSMA dosimetry imaging only (single tracer dose). A feasibility analysis of dosimetry will be performed after meeting the accrual goal of Cohort 1 to determine if the study will proceed into Cohort 2. If Cohort 2 proceeds, based on the dosimetry analysis, the major requirements of the study are to undergo treatment with 177Lu-PNT2002, have bloodwork, physical exams, and imaging done at study-specific time points, and to answer questionnaires. Patients will be in the study for about two years after enrolling.

NCT ID: NCT06199453 Not yet recruiting - Clinical trials for Adenoid Cystic Carcinoma

The Evaluation of the Effectiveness, Safety and Tolerability of Treatment, Using a PSMA-Lu177, in Patients With ACC- an Open, Non-commercial Clinical Trial

LuRM_ACC/2023
Start date: January 2024
Phase: Phase 2
Study type: Interventional

Non-commercial phase 2 clinical trial to evaluate the effectiveness, safety and tolerability of treatment using prostate-specific membrane antigen (PSMA) labeled with 177Lutetium in patients with recurrence and/or metastases in adenoid cystic carcinoma originating from the salivary glands of the head and neck region. Patients with PSMA receptor expression confirmed by PET/CT after administration of 68Ga-PSMA I&T will be eligible for treatment.

NCT ID: NCT05553782 Not yet recruiting - Clinical trials for Adenoid Cystic Carcinoma

Drug Screening Using Novel IMD in ACC and Salivary Cancers

Start date: November 1, 2023
Phase: Early Phase 1
Study type: Interventional

This research study is studying the effect of different drugs as possible treatments for adenoid cystic carcinoma (ACC), a type of head and neck cancer. The name of the study intervention involved in this study is: -implantable microdevice